Compare Kohl's Corporation (KSS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Smith & Nephew plc — how do they compare? Kohl's Corporation trades at $20.24 (market cap $2.28B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 4.9× Kohl's Corporation's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and Smith & Nephew plc for 121 Days on average.
| KSS | SNN | |
|---|---|---|
Market Cap | $2.28B | $11.10B |
Volume | 4,960,280 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $37.17 |
52-Week Low | $11.72 | $26.42 |
Typical Hold Time | 48 Days | 121 Days |
Enterprise Value | $7.88B | $14.13B |
Dividend Yield | 2.49% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $20.28, up 0.8% with a bullish technical signal despite overbought RSI readings. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, while recent earnings beats and raised guidance signal operational improvement. However, revenue has declined for 18 consecutive quarters, presenting a challenging growth environment.
The investment case balances deep value against persistent sales declines. While low valuations and margin improvements support upside potential, sustained revenue weakness and competitive pressures remain key risks. Analyst consensus is mixed with 30% buy ratings but a $15.50 price target below current levels, suggesting cautious optimism.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
